Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Key Inclusion Criteria: 1. Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% during the study and 60 days after discontinuation of study treatment. 2. Considered healthy by the Principal Investigator, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs; 3. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening; 4. Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg; Exclusion Criteria: 1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity; 2. Mean systolic blood pressure of three measurements \>140 mmHg, or a mean diastolic blood pressure of three measurements \>90 mmHg at screening. 3. Known or suspected malignancy; 4. Positive blood screen for human immunodeficiency virus (HIV), or hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV); 5. A history of seizure. However, a history of febrile seizure is allowed; 6. Positive pregnancy test result, or plan to become pregnant if female; 7. A hospital admission or major surgery within 30 days prior to screening; 8. Participation in any other investigational drug trial within 30 days prior to screening; 9. DSM-V substance use disorder within 6 months prior to screening; 10. A positive result for alcohol or drugs of abuse at screening or admission; 11. Tobacco use within 6 months prior to screening; 12. An unwillingness or inability to comply with food and beverage restrictions during study participation; 13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening; 14. Use of prescription or over-the-counter (OTC) medications, and herbal medicines (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing; 15. A history of suicide attempt in the past 12 months and/or seen by the investigator as having a significant history of risk of suicide or homicide; 16. A history of intolerance or hypersensitivity to amlodipine or any excipients; 17. An unwillingness of male participants to use appropriate contraceptive measures if engaging in sex intercourse with a female partner of childbearing potential during the study and 60 days after discontinuation of study treatment.